Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset
Inflammatory joint diseases are major causes of invalidity and morbidity. Rheumatoid arthritis (RA), the most frequent of chronic arthritides, affects close to 1% of the Canadian population. Direct and indirect costs of RA represent close to 1% of the gross national product. Recent evidence suggest that initiation of e
| Condition(s) | Rheumatoid Arthritis, Inflammatory Arthritis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Inflammatory joint diseases are major causes of invalidity and morbidity. Rheumatoid arthritis (RA), the most frequent of chronic arthritides, affects close to 1% of the Canadian population. Direct and indirect costs of RA represent close to 1% of the gross national product. Recent evidence suggest that initiation of early (e.g., during the first 3-12 months of disease) aggressive treatment decreases both mortality and long term invalidity in RA and other chronic arthritides. However, a significant proportion of patients with early polyarthritis (EPA) have a benign evolution, even if they fulfill criteria for RA. On the contrary, most patients whose arthritis persist for more than 12 months have a progressive and destructive disease. Currently available clinical, serological and genetic ma |
| Who can participate | Inclusion Criteria: * Early Rheumatoid arthritis * Early Inflammatory Arthritis Exclusion Criteria: * Refusal or inability to consent * Infectious arthritis * Microcrystalline arthritis |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Lead sponsor | Gilles Boire |
| Locations | Sherbrooke, Quebec, Canada |
| Start date | 1998-07 |
| NCT ID | NCT00512239 |
| Official listing | https://clinicaltrials.gov/study/NCT00512239 |